uniQure Priced, Nasdaq: QURE
Biotech developing gene therapies for the treatment of orphan diseases.
Industry: Health Care
First Day Return: -14.1%
QURE
Biotech developing gene therapies for the treatment of orphan diseases.
| IPO Data | |
|---|---|
| IPO Date | 02/04/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $92 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Amsterdam, Netherlands |
| Founded | 1998 |
| Employees at IPO | 87 |
| Website www.uniqure.com | |
uniQure (QURE) Performance
